论文部分内容阅读
美国劳德代尔堡消息:当前心脏病学家喜用的治疗药物中,钙通道阻滞剂似乎有希望成为治疗支气管哮喘的药物。迈阿密大学药物学副教授Tahir Ahmed关于钙阻滞剂对哮喘症状的作用进行多次研究,他认为,此类新化合物将来可能成为治疗支气管哮喘的主要方法之一。 Ahmed对新的钙拮抗剂Gallopamil(异搏停的甲氧基衍生物)进行初步的动物与人的试验,结果表明Gallopamil的疗效是异搏停(Verapamil)的10～20倍。在美国临床免疫学和变态反应学会年会上,Ahmed公布他及其他实验室几十次研究的数据,证实钙拮抗剂对治疗哮喘有相当重要的作用。
Fort Lauderdale, United States: Calcium channel blockers appear promising as drugs for the treatment of bronchial asthma in current therapies that cardiologists like to use. Tahir Ahmed, an associate professor of medicine at the University of Miami, on the role of calcium blockers in the management of asthma symptoms, said he believes such new compounds may become one of the major treatments for bronchial asthma in the future. Ahmed conducted a preliminary animal and human trial of the new calcium antagonist Gallopamil (verapamil methoxy derivative) and found that Gallopamil was 10-20 times more potent than Verapamil. At the annual meeting of the American Society of Clinical Immunology and Allergology, Ahmed published data from dozens of studies in his laboratory and other laboratories confirming that calcium antagonists play a significant role in the treatment of asthma.